Shares of BioCardia, a biotechnology company based in Sunnyvale, California, took a hit when the company announced that its ongoing Phase 3 pivotal CardiAMP Cell Therapy Heart Failure trial was unlikely to meet its primary endpoint. As a result, the stock experienced a 23% drop to 60 cents in early trading.
Over the past year, BioCardia's shares had already fallen by 63% prior to the recent setback. Despite these challenges, the company remains committed to its mission of advancing innovative cell therapies.
According to BioCardia, the trial's one-year follow-up and certain measures indicate that the 250-patient randomized controlled study is unlikely to achieve its primary efficacy endpoint. However, Amish Raval, a professor of medicine at the University of Wisconsin in Madison and a co-national principal investigator, acknowledged that there were promising trends towards patient benefits for the CardiAMP cell therapy throughout the study. These promising trends included a reduction in all-cause death, although they did not reach statistical significance.
Although this setback is disappointing for BioCardia and its investors, it highlights the challenges and complexities of clinical trials in the field of cell therapy. The company will continue its focus on pioneering new possibilities in cellular medicine.
Asia-Pacific Stocks Mostly Decrease
Our Latest News
Synopsys Shares Gain Ground on Strong Q3 Results and Upbeat Guidance
Synopsys impresses investors with strong Q3 financial results, exceeding expectations and providing positive guidance for future growth. The company's success i...
Glanbia Reports Rise in Pretax Profit for H1 2024
Glanbia, the Irish nutrition group, reports an increase in pretax profit for H1 2024 due to exceptional net post-tax gain with a decline in revenue. New CEO app...
Amazon Invests in Direct-Air-Capture Technology
Amazon.com has invested in direct-air-capture technology to achieve net-zero carbon emissions, supporting a healthier environment and leading the way towards a...